Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.

Butler KM, Husson RN, Balis FM, Brouwers P, Eddy J, el-Amin D, Gress J, Hawkins M, Jarosinski P, Moss H, et al.

N Engl J Med. 1991 Jan 17;324(3):137-44.

2.

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.

McKinney RE Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P, et al.

N Engl J Med. 1991 Apr 11;324(15):1018-25.

3.

Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial.

Drusano GL, Yuen GJ, Lambert JS, Seidlin M, Dolin R, Valentine FT.

Ann Intern Med. 1992 Apr 1;116(7):562-6.

PMID:
1347442
4.

Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection.

Husson RN, Mueller BU, Farley M, Woods L, Kovacs A, Goldsmith JC, Ono J, Lewis LL, Balis FM, Brouwers P, et al.

Pediatrics. 1994 Feb;93(2):316-22.

PMID:
7907174
5.
6.

The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.

Yarchoan R, Mitsuya H, Pluda JM, Marczyk KS, Thomas RV, Hartman NR, Brouwers P, Perno CF, Allain JP, Johns DG, et al.

Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S522-33.

PMID:
1974724
7.

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

Cooley TP, Kunches LM, Saunders CA, Ritter JK, Perkins CJ, McLaren C, McCaffrey RP, Liebman HA.

N Engl J Med. 1990 May 10;322(19):1340-5.

8.

A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, Spector SA, Pettinelli CB, Davies G, Richman DD, Leedom JM, et al.

N Engl J Med. 1990 Oct 11;323(15):1015-21.

9.

Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.

Cooley TP, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, McCaffrey RP, Liebman HA.

Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S552-60.

PMID:
1974727
10.

Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.

Valentine FT, Seidlin M, Hochster H, Laverty M.

Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S534-9.

PMID:
1974725
11.

Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection.

Husson RN, Chung Y, Mordenti J, Butler KM, Chen S, Duliege AM, Brouwers P, Jarosinski P, Mueller BU, Ammann A, et al.

J Pediatr. 1992 Oct;121(4):627-33.

PMID:
1357124
12.

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.

Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, Schultze ME, Woods L, Loewen DF, Kaul S, et al.

Pediatrics. 1995 Aug;96(2 Pt 1):247-52.

PMID:
7630678
13.

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.

Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J, et al.

N Engl J Med. 1993 Jul 29;329(5):297-303.

14.

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, Wyvill KM, Steinberg SM, Agbaria R, Mitsuya H, et al.

J Infect Dis. 1994 Jan;169(1):9-17. Erratum in: J Infect Dis 1994 Jul;170(1):260.

PMID:
7903976
15.

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.

Meng TC, Fischl MA, Boota AM, Spector SA, Bennett D, Bassiakos Y, Lai SH, Wright B, Richman DD.

Ann Intern Med. 1992 Jan 1;116(1):13-20.

PMID:
1345755
16.

2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.

Dolin R, Lambert JS, Morse GD, Reichman RC, Plank CS, Reid J, Knupp C, McLaren C, Pettinelli C.

Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S540-9; discussion S549-51.

PMID:
1974726
17.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
18.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS.

N Engl J Med. 1996 Oct 10;335(15):1091-8. Erratum in: N Engl J Med 1997 Oct 9;337(15):1097.

19.

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM.

Pediatrics. 1996 Jun;97(6 Pt 1):886-90.

PMID:
8657531
20.

Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

Mueller BU, Butler KM, Stocker VL, Balis FM, Brouwers P, Jarosinski P, Husson RN, Lewis LL, Venzon D, Pizzo PA.

Pediatrics. 1994 Nov;94(5):724-31.

PMID:
7936903

Supplemental Content

Support Center